- Home
- SIBN vs IMTX Comparison
SIBN vs IMTX Comparison
Compare SIBN & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIBN
- IMTX
- Stock Information
- Founded
- SIBN 2008
- IMTX N/A
- Country
- SIBN United States
- IMTX Germany
- Employees
- SIBN N/A
- IMTX N/A
- Industry
- SIBN Medical/Dental Instruments
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SIBN Health Care
- IMTX Health Care
- Exchange
- SIBN Nasdaq
- IMTX Nasdaq
- Market Cap
- SIBN 733.0M
- IMTX 653.9M
- IPO Year
- SIBN 2018
- IMTX N/A
- Fundamental
- Price
- SIBN $15.46
- IMTX $6.33
- Analyst Decision
- SIBN Strong Buy
- IMTX Strong Buy
- Analyst Count
- SIBN 5
- IMTX 4
- Target Price
- SIBN $24.40
- IMTX $14.67
- AVG Volume (30 Days)
- SIBN 483.1K
- IMTX 537.7K
- Earning Date
- SIBN 08-04-2025
- IMTX 08-13-2025
- Dividend Yield
- SIBN N/A
- IMTX N/A
- EPS Growth
- SIBN N/A
- IMTX N/A
- EPS
- SIBN N/A
- IMTX N/A
- Revenue
- SIBN $185,262,000.00
- IMTX $152,823,253.00
- Revenue This Year
- SIBN $19.48
- IMTX N/A
- Revenue Next Year
- SIBN $16.86
- IMTX $1.92
- P/E Ratio
- SIBN N/A
- IMTX N/A
- Revenue Growth
- SIBN 22.93
- IMTX 83.61
- 52 Week Low
- SIBN $11.70
- IMTX $3.30
- 52 Week High
- SIBN $20.05
- IMTX $13.09
- Technical
- Relative Strength Index (RSI)
- SIBN 39.00
- IMTX 52.73
- Support Level
- SIBN $15.20
- IMTX $5.56
- Resistance Level
- SIBN $16.12
- IMTX $6.50
- Average True Range (ATR)
- SIBN 0.93
- IMTX 0.35
- MACD
- SIBN -0.15
- IMTX -0.07
- Stochastic Oscillator
- SIBN 10.84
- IMTX 62.10
About SIBN SI-BONE Inc.
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.